Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters

Patent metadata

Field	Value
Publication number	US-9428569-B2
Application number	US-201313786351-A
Country	US
Kind code	B2
Filing date	Mar 5, 2013
Priority date	Sep 22, 2008
Publication date	Aug 30, 2016
Grant date	Aug 30, 2016

Abstract

Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.

First claim

What is claimed is:

1. A composition comprising a nucleic acid comprising a promoter operably linked to a polynucleotide that encodes a chimeric protein, wherein the chimeric protein comprises:
(i) a membrane targeting region;
(ii) a multimeric ligand-binding region;
(iii) a cytoplasmic CD40 polypeptide region lacking the extracellular domain; and
(iv) a truncated MyD88 polypeptide lacking the TIR domain comprising the amino acid sequence SEQ ID NO: 6.

2. The composition of claim 1 , wherein the truncated MyD88 polypeptide is encoded by the nucleotide sequence of SEQ ID NO: 5.

3. The composition of claim 1 , wherein the membrane targeting region is selected from the group consisting of myristoylation-targeting region, palmitoylation targeting region, prenylation region, and receptor transmembrane region.

4. The composition of claim 1 , wherein the CD40 cytoplasmic polypeptide region comprises an amino acid sequence of the cytoplasmic region of SEQ ID NO: 2.

5. The composition of claim 1 , wherein the nucleic acid is contained within a viral vector.

6. The composition of claim 5 , wherein the viral vector is an adenoviral vector.

7. A composition comprising a cell transduced or transfected with a nucleic acid of claim 1 .

8. The composition of claim 7 , wherein the cell is an antigen-presenting cell.

9. The composition of claim 7 , wherein the cell is a dendritic cell.

10. The composition of claim 1 , wherein the ligand-binding region comprises a FV′Fvls amino acid sequence.

11. The composition of claim 1 , wherein the ligand is a small molecule.

12. The composition of claim 1 , wherein the ligand is dimeric.

13. The composition of claim 12 , wherein the ligand is dimeric FK506, or a dimeric FK506 analog.

14. The composition of claim 1 , wherein the ligand is AP1903 or AP20187.

15. The composition of claim 1 , wherein the multimeric ligand-binding region comprises a FKBP12 ligand-binding region.

16. The composition of claim 15 , wherein the FKBP12 ligand-binding region comprises an amino acid substitution at position 36.

17. The composition of claim 16 , wherein the multimeric ligand-binding region comprises FKBP12(V36).

Assignees

• Baylor College Medicine

Inventors

• Spencer David
• Narayanan Priyadharshini

Classifications

• C12N2501/52

  CD40, CD40-ligand (CD154) · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• C07K14/4705

  stimulating, promoting or activating activity · CPC title

• C12N2501/70

  Enzymes · CPC title

• C07K2319/033

  containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif · CPC title